| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1647 | 2022 |
| H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers M Seiler, A Yoshimi, R Darman, B Chan, G Keaney, M Thomas, ... Nature medicine 24 (4), 497-504, 2018 | 465 | 2018 |
| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 428 | 2020 |
| Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ... Journal of clinical oncology 39 (14), 1584, 2021 | 346 | 2021 |
| The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype AA Basiorka, KL McGraw, EA Eksioglu, X Chen, J Johnson, L Zhang, ... Blood, The Journal of the American Society of Hematology 128 (25), 2960-2975, 2016 | 322 | 2016 |
| Structure of adeno-associated virus serotype 8, a gene therapy vector HJ Nam, MD Lane, E Padron, B Gurda, R McKenna, E Kohlbrenner, ... Journal of virology 81 (22), 12260-12271, 2007 | 291 | 2007 |
| Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study NK Gillis, M Ball, Q Zhang, Z Ma, YL Zhao, SJ Yoder, ME Balasis, ... The lancet oncology 18 (1), 112-121, 2017 | 285 | 2017 |
| Structurally mapping the diverse phenotype of adeno-associated virus serotype 4 L Govindasamy, E Padron, R McKenna, N Muzyczka, N Kaludov, ... Journal of virology 80 (23), 11556-11570, 2006 | 226 | 2006 |
| Structurally mapping the diverse phenotype of adeno-associated virus serotype 4 L Govindasamy, E Padron, R McKenna, N Muzyczka, N Kaludov, ... Journal of virology 80 (23), 11556-11570, 2006 | 226 | 2006 |
| Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents J Merlevede, N Droin, T Qin, K Meldi, K Yoshida, M Morabito, E Chautard, ... Nature communications 7 (1), 10767, 2016 | 225 | 2016 |
| Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes MM Patnaik, E Padron, RR LaBorde, TL Lasho, CM Finke, CA Hanson, ... Leukemia 27 (7), 1504-1510, 2013 | 225 | 2013 |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ... Leukemia 33 (7), 1747-1758, 2019 | 215 | 2019 |
| Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes DA Sallman, R Komrokji, C Vaupel, T Cluzeau, SM Geyer, KL McGraw, ... Leukemia 30 (3), 666-673, 2016 | 215 | 2016 |
| An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults MR Savona, L Malcovati, R Komrokji, RV Tiu, TI Mughal, A Orazi, ... Blood, The Journal of the American Society of Hematology 125 (12), 1857-1865, 2015 | 182 | 2015 |
| GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia E Padron, JS Painter, S Kunigal, AW Mailloux, K McGraw, JM McDaniel, ... Blood, The Journal of the American Society of Hematology 121 (25), 5068-5077, 2013 | 171 | 2013 |
| Structure of adeno-associated virus type 4 E Padron, V Bowman, N Kaludov, L Govindasamy, H Levy, P Nick, ... Journal of virology 79 (8), 5047-5058, 2005 | 154 | 2005 |
| Autoimmune diseases and myelodysplastic syndromes RS Komrokji, A Kulasekararaj, NH Al Ali, S Kordasti, E Bart‐Smith, ... American journal of hematology 91 (5), E280-E283, 2016 | 138 | 2016 |
| NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018 RA Mesa, C Jamieson, R Bhatia, MW Deininger, CD Fletcher, AT Gerds, ... Journal of the National Comprehensive Cancer Network 15 (10), 1193-1207, 2017 | 137 | 2017 |
| An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies E Padron, G Garcia-Manero, MM Patnaik, R Itzykson, T Lasho, A Nazha, ... Blood cancer journal 5 (7), e333-e333, 2015 | 132 | 2015 |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype DA Sallman, AF McLemore, AL Aldrich, RS Komrokji, KL McGraw, ... Blood, The Journal of the American Society of Hematology 136 (24), 2812-2823, 2020 | 126 | 2020 |
